{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:55:51Z","timestamp":1765331751514,"version":"3.46.0"},"reference-count":49,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>It is of interest to investigate trends in AAS usage profile. Here we aimed to retrospectively study the prevalence of AAS\u2010positive samples based on 21,172 consecutive analyses from routine AAS testing 2014\u20132023. Moreover, 310 urine samples from 2022 to 2023 were reanalyzed for a broader AAS panel as well as for the presence of narcotics. Between 2014 and 2023, the frequency of reported AAS\u2010positive samples varied between 6% and 11%, with no trend discerned. The prevalence of samples containing several AAS also shows a similar distribution. The most common AAS detected were consistently testosterone, nandrolone, and drostanolone. Of the 310 urine samples reanalyzed, 80 male and 6 female samples were positive for AAS. Thirteen of the samples showed T\/E 4\u201310, indicative of testosterone use, with no other AAS. Consequently, 4% of the samples might have been reported as false negatives. Of the AAS\u2010positive samples, amphetamine was found in 10% and 0% of the male and female samples, respectively. Cannabis was more often detected in AAS\u2010positive female samples (50%) than in male samples (25%), whereas cocaine was more commonly detected in male than in female samples (33 versus 17%). The prevalence of cannabis and amphetamine was like previous AAS studies conducted in Sweden, whereas the presence of cocaine in male samples was substantially higher. Co\u2010use of AAS and narcotics is a well\u2010known problem and highlights the importance of preventive actions and education\/awareness of AAS.<\/jats:p>","DOI":"10.1002\/dta.3955","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:00:05Z","timestamp":1758762005000},"page":"2421-2428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of AAS\u2010Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub\u2010Study of Dual Use of AAS and Narcotics"],"prefix":"10.1002","volume":"17","author":[{"given":"Kim\u00a0Petterson","family":"Bohlin","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Doping Control Laboratory, MU Clinical Pharmacology Karolinska University Laboratory, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Vill\u00e9n","sequence":"additional","affiliation":[{"name":"Drugs of Abuse Laboratory, MU Clinical Pharmacology Karolinska University Laboratory, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Hopcraft","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory, MU Clinical Pharmacology Karolinska University Laboratory, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Pohanka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Doping Control Laboratory, MU Clinical Pharmacology Karolinska University Laboratory, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-2345","authenticated-orcid":false,"given":"Lena","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Doping Control Laboratory, MU Clinical Pharmacology Karolinska University Laboratory, Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.01.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0633-z"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz324"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-015-9320-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026945"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-304"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.04.013"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60801-6"},{"key":"e_1_2_8_10_1","unstructured":"L.Ekstr\u00f6mandM.Lehtihet \u201cL\u00e4kemedelsboken\u2014Doping\u201d accessed March 2025 2024 July 9 2024 https:\/\/lakemedelsboken.se\/generella\u2010kapitel\/doping\/."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0056-3"},{"issue":"6","key":"e_1_2_8_12_1","article-title":"Male Anabolic Androgenic Steroid Users With Personality Disorders Report More Aggressive Feelings, Suicidal Thoughts, and Criminality","volume":"56","author":"Borjesson A.","year":"2020","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2012.01.004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2006.tb00642.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3125"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000210194.56834.5d"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.8.757"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.12.024"},{"key":"e_1_2_8_19_1","unstructured":"1991:1969 S \u201cLag om F\u00f6rbud Mot Vissa Dopningsmedel (SFS 1991:1969)\u201d https:\/\/www.riksdagen.se\/sv\/dokument\u2010och\u2010lagar\/dokument\/svensk\u2010forfattningssamling\/lag\u201019911969\u2010om\u2010forbud\u2010mot\u2010vissa\u2010dopningsmedel_sfs\u20101991\u20101969\/."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3600"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2121"},{"key":"e_1_2_8_22_1","unstructured":"World Anti\u2010Doping Agency (WADA) \u201cTechnical Document TD2023IDCR\u201d accessed March 2025. 2023 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2023\u201002\/td2023idcrv1.1_eng_final.pdf."},{"key":"e_1_2_8_23_1","unstructured":"WADA \u201cWorld Anti\u2010Doping Code International Standard Prohibited List\u201d 2025. 2024 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2024\u201009\/2025list_en_final_clean_12_september_2024.pdf."},{"key":"e_1_2_8_24_1","unstructured":"(WADA) \u201cWorld Anti\u2010Doping Agency Technical Document\u2014TD2022MRPL\u201d accessed March 20025 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2022\u201001\/td2022mrpl_v1.1_eng_0.pdf."},{"key":"e_1_2_8_25_1","unstructured":"L.Selling \u201cCAN:s Nationella Skolunders\u00f6kning 2024\u201d accessed February 2025 2024 https:\/\/www.can.se\/app\/uploads\/2024\/11\/can\u2010rapport\u2010230\u2010cans\u2010nationella\u2010skolundersokning\u20102024.pdf."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30214-1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2022.2132135"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2763"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JSM.0b013e3181fb5370"},{"key":"e_1_2_8_30_1","first-page":"1","article-title":"#Sponseredathlete: The Marketing of Image and Performance Enhancing Drugs on Facebook and Instagram","author":"Gibbs N.","year":"2023","journal-title":"Trends in Organized Crime"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13102-016-0062-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1017801"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00781.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17482631.2021.1927490"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988320966536"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2007.04.001"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3040"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3660"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3690"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000199045"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12977-w"},{"key":"e_1_2_8_42_1","unstructured":"B.Annica \u201cSide Effects and Experiences of Doping With Anabolic Androgenic Steroids in Men and Women\u201d https:\/\/openarchive.ki.se\/articles\/thesis\/Side_effects_and_experiences_of_doping_with_anabolic_androgenic_steroids_in_men_and_women\/26916751?file=48961018."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000012362"},{"key":"e_1_2_8_44_1","article-title":"Drug Use and Drug Trends in Sweden 2010\u20132020 \u2010 Results From Urine Drug Testing in the Workplace","volume":"118","author":"Helander A.","year":"2021","journal-title":"L\u00e4kartidningen"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281304"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/1056-8719(93)90052-G"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab264"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsams.2017.03.008"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-015-0006-5"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12715"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:45:16Z","timestamp":1765331116000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/dta.3955"],"URL":"https:\/\/doi.org\/10.1002\/dta.3955","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"type":"print","value":"1942-7603"},{"type":"electronic","value":"1942-7611"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"2025-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}